<DOC>
	<DOCNO>NCT01023802</DOCNO>
	<brief_summary>In patient breast cancer undergo neoadjuvant chemotherapy neoadjuvant hormone therapy molecular breast imaging ( MBI ) accurate test assess response rate neoadjuvant therapy .</brief_summary>
	<brief_title>The Use Molecular Breast Imaging Evaluation Tumor Response Neoadjuvant Therapy Women With Breast Cancer</brief_title>
	<detailed_description>The investigator propose evaluate Molecular Breast Imaging patient undergo neoadjuvant therapy breast cancer aim document 1 ) change uptake 99mTc-sestamibi prior initiation neoadjuvant therapy , 3-5 week neoadjuvant therapy completion neoadjuvant therapy prior breast cancer surgery reflection tumor response neoadjuvant therapy . 2 ) Tumor response 3-5 week neoadjuvant therapy predictive tumor response completion neoadjuvant therapy . 3 ) Post-neoadjuvant tumor size determine MBI corresponds size find surgery .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women breast cancer schedule undergo neoadjuvant chemotherapy therapy neoadjuvant hormone therapy undergone breast imaging procedure , repeat imaging procedure plan prior definite surgery . MRI breast accurate tumor size evaluation recommend necessarily require study inclusion . Are able return 35 week followup MBI study final MBI study completion neoadjuvant therapy . Patient age &gt; 18 Unable understand sign consent form Pregnant lactate Physically unable sit upright still 40 minute</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>neoadjuvant therapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>hormone therapy</keyword>
	<keyword>breast cancer</keyword>
	<keyword>MBI</keyword>
	<keyword>Molecular Breast Imaging</keyword>
</DOC>